CX Institutional Has $6.35 Million Stock Holdings in Harmony Biosciences Holdings, Inc. $HRMY

CX Institutional lifted its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 10.9% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 230,433 shares of the company’s stock after buying an additional 22,650 shares during the quarter. CX Institutional owned about 0.40% of Harmony Biosciences worth $6,351,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Amundi raised its stake in shares of Harmony Biosciences by 115.6% in the first quarter. Amundi now owns 39,668 shares of the company’s stock worth $1,229,000 after acquiring an additional 21,266 shares during the last quarter. Advisors Asset Management Inc. raised its position in Harmony Biosciences by 81.7% in the 1st quarter. Advisors Asset Management Inc. now owns 6,088 shares of the company’s stock worth $202,000 after purchasing an additional 2,737 shares during the last quarter. AQR Capital Management LLC raised its position in Harmony Biosciences by 4.7% in the 1st quarter. AQR Capital Management LLC now owns 166,340 shares of the company’s stock worth $5,521,000 after purchasing an additional 7,484 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Harmony Biosciences by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,651 shares of the company’s stock worth $752,000 after buying an additional 984 shares in the last quarter. Finally, Jones Financial Companies Lllp boosted its position in Harmony Biosciences by 34,496.0% in the 1st quarter. Jones Financial Companies Lllp now owns 51,894 shares of the company’s stock valued at $1,722,000 after buying an additional 51,744 shares during the last quarter. Institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Stock Performance

Shares of NASDAQ:HRMY opened at $37.55 on Thursday. The firm’s 50 day simple moving average is $35.81 and its 200 day simple moving average is $33.77. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $25.52 and a fifty-two week high of $40.93. The company has a market capitalization of $2.16 billion, a price-to-earnings ratio of 11.81, a P/E/G ratio of 0.38 and a beta of 0.84. The company has a debt-to-equity ratio of 0.18, a current ratio of 3.75 and a quick ratio of 3.72.

Harmony Biosciences (NASDAQ:HRMY) last issued its earnings results on Tuesday, November 4th. The company reported $0.87 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.05). The firm had revenue of $239.46 million during the quarter, compared to the consensus estimate of $222.68 million. Harmony Biosciences had a net margin of 22.50% and a return on equity of 24.88%. As a group, sell-side analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Insider Buying and Selling

In other Harmony Biosciences news, CEO Jeffrey M. Dayno sold 25,933 shares of Harmony Biosciences stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $40.11, for a total transaction of $1,040,172.63. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 23.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. UBS Group dropped their target price on Harmony Biosciences from $50.00 to $43.00 and set a “buy” rating for the company in a research report on Wednesday, October 15th. Oppenheimer reissued an “outperform” rating and set a $62.00 price objective on shares of Harmony Biosciences in a report on Monday, November 24th. HC Wainwright reaffirmed a “buy” rating on shares of Harmony Biosciences in a research note on Wednesday, December 3rd. Deutsche Bank Aktiengesellschaft lowered their price target on shares of Harmony Biosciences from $54.00 to $36.00 and set a “buy” rating for the company in a research report on Thursday, September 25th. Finally, Wall Street Zen upgraded shares of Harmony Biosciences from a “hold” rating to a “buy” rating in a report on Saturday, December 13th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $45.63.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.